CIC
MESO

Chase Investment Counsel’s Mesoblast MESO Stock Holding History

Chase Investment Counsel’s Portfolio MESO Stock Details MESO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,600
Closed -$405K – 136
2024
Q2 		$405K Hold
59,600
– – 0.14% 104
2024
Q1 		$298K Buy
+59,600
New +$127K 0.11% 123

Other funds holding MESO

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SXL
Summit X LLC Chesterfield, Missouri $536M AUM 15.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PWM
Prosperity Wealth Management San Ramon, California $300M AUM 28.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
LCM
Lazari Capital Management Woodland Hills, California $325M AUM 32.83% 1-Year Est. Return

Chase Investment Counsel's MESO Position: Q3 2024 in Review

Chase Investment Counsel sold out of Mesoblast (MESO) in Q3 2024, closing a stake of 59,600 shares — an estimated $405K sold.

Chase Investment Counsel first reported a position in MESO in Q1 2024 and held it in 2 quarters. The position peaked at $405K in Q2 2024. 43 funds tracked by Wall St. Rank hold MESO as of Q3 2024.

  • Chase Investment Counsel reported no remaining Mesoblast position as of Q3 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 59,600 Mesoblast shares in Q3 2024, an estimated $405K.
  • Chase Investment Counsel first reported a position in Mesoblast in Q1 2024 and held it in 2 quarters.
  • Chase Investment Counsel's Mesoblast position peaked at $405K in Q2 2024.
  • 43 funds tracked by Wall St. Rank held Mesoblast as of Q3 2024.

Based on Chase Investment Counsel's 13F filing for Q3 2024, filed 5 Nov 2024.